DRIO

SEC source: 0001104659-24-069618 · tm2416654-2_4seq1.xml · derivative · entry 2

Nelson Steven Charles · CIK 0002025906 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2034-06-05

F2 · derivative.exercise_date: The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principles basis) for the year ending December 31, 2024.

F2 · derivative.expiration_date: The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principles basis) for the year ending December 31, 2024.

SEC source: 0001104659-24-069618 · tm2416654-2_4seq1.xml · derivative · entry 1

Nelson Steven Charles · CIK 0002025906 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The options vest as follows: 500,00 shares vest over three years in three equal yearly amounts, subject to the Reporting Person's continued services to the Issuer on the applicable vesting date.

F1 · derivative.expiration_date: The options vest as follows: 500,00 shares vest over three years in three equal yearly amounts, subject to the Reporting Person's continued services to the Issuer on the applicable vesting date.

SEC source: 0001104659-24-032405 · tm248350-2_4seq1.xml · nonDerivative · entry 1

Matheis Dennis · CIK 0001817012 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,620

F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period.

SEC source: 0001104659-24-032412 · tm248350-6_4seq1.xml · nonDerivative · entry 1

KAPLAN JON H. · CIK 0001751699 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period.

SEC source: 0001104659-24-032411 · tm248350-5_4seq1.xml · nonDerivative · entry 1

Karah Hila · CIK 0001668116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,290

F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period.

SEC source: 0001104659-24-032416 · tm248350-9_4seq1.xml · nonDerivative · entry 1

Ben-David Zvi · CIK 0001667943 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 746,035

F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period.

SEC source: 0001104659-24-032409 · tm248350-4_4seq1.xml · nonDerivative · entry 1

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,912,059

F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period.

SEC source: 0001104659-24-032397 · tm248350-1_4seq1.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,341

F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period.

SEC source: 0001104659-24-032408 · tm248350-3_4seq1.xml · nonDerivative · entry 1

MCGRATH DENNIS M · CIK 0001269340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,744

F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period.

SEC source: 0001104659-24-032413 · tm248350-7_4seq1.xml · derivative · entry 2

ANDERSON RICHARD ALAN · CIK 0001266647 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,000

Underlying: Common Stock · 320,000 shares

Expires not disclosed

F2 · derivative.exercise_date: The option will vest upon reaching certain performance milestones between December 31, 2024 and March 31, 2025.

F2 · derivative.expiration_date: The option will vest upon reaching certain performance milestones between December 31, 2024 and March 31, 2025.

SEC source: 0001104659-24-032413 · tm248350-7_4seq1.xml · derivative · entry 1

ANDERSON RICHARD ALAN · CIK 0001266647 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Stock · 750,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The options will vest over a two-year period commencing on the grant date, with 50% vesting on the grant date and 50% vesting in eight equal quarterly installments following the grant date, subject to the employee's continued employment by the Company.

F1 · derivative.expiration_date: The options will vest over a two-year period commencing on the grant date, with 50% vesting on the grant date and 50% vesting in eight equal quarterly installments following the grant date, subject to the employee's continued employment by the Company.

SEC source: 0001104659-24-032414 · tm248350-8_4seq1.xml · nonDerivative · entry 1

Shaked Yoav · CIK 0001744499 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,193

F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period.

SEC source: 0001104659-24-026040 · tm246888-2_4seq1.xml · derivative · entry 2

Ben-Kiki Tomer · CIK 0002011990 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2034-02-15

F2 · derivative.exercise_date: The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principals basis) for the year ending December 31, 2024, the achievement of certain operating expense targets for the years ending December 31, 2024 and December 31, 2025, the ability to generate software value from funds invested and meet product roadmap and the retention of key employees post transaction, subject in each case to the Reporting Person's continued services to the Issuer on the applicable vesting date.

F2 · derivative.expiration_date: The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principals basis) for the year ending December 31, 2024, the achievement of certain operating expense targets for the years ending December 31, 2024 and December 31, 2025, the ability to generate software value from funds invested and meet product roadmap and the retention of key employees post transaction, subject in each case to the Reporting Person's continued services to the Issuer on the applicable vesting date.

SEC source: 0001104659-24-026040 · tm246888-2_4seq1.xml · derivative · entry 1

Ben-Kiki Tomer · CIK 0002011990 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 717,947

Underlying: Common Stock · 717,947 shares

Expires 2034-02-15

F1 · derivative.exercise_date: The options vest as follows: 291,742 shares vest immediately, and the remaining 426,205 shares vest over two years in eight equal quarterly amounts, subject to subject to the Reporting Person's continued services to the Issuer on the applicable vesting date.

F1 · derivative.expiration_date: The options vest as follows: 291,742 shares vest immediately, and the remaining 426,205 shares vest over two years in eight equal quarterly amounts, subject to subject to the Reporting Person's continued services to the Issuer on the applicable vesting date.

SEC source: 0001104659-24-029952 · tm247605-1_4seq1.xml · derivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · AKS Family Partnership, L.P

Disclosed balance after: 250

Underlying: Common Stock · Not disclosed shares

Expires not disclosed

F1 · derivative.exercise_date: Subject to beneficial ownership limitations provided for in the offering documents relating to the sale of the Series-C Preferred Stock, each share of Series-C Preferred Stock shall automatically convert into shares of the registrant's common stock at the conversion price of $2.02 upon the earlier of (i) the 15-month anniversary of the effective date of the certificate of designation, or (ii) the consent to conversion by holders of at least 50.1% of the outstanding shares of Series-C Preferred.

F1 · derivative.expiration_date: Subject to beneficial ownership limitations provided for in the offering documents relating to the sale of the Series-C Preferred Stock, each share of Series-C Preferred Stock shall automatically convert into shares of the registrant's common stock at the conversion price of $2.02 upon the earlier of (i) the 15-month anniversary of the effective date of the certificate of designation, or (ii) the consent to conversion by holders of at least 50.1% of the outstanding shares of Series-C Preferred.

F2 · derivative.underlying_shares: The Series C Preferred Stock initially converts into shares of common stock at a conversion price of $2.02. In addition, the holders of Series c Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to seven and a half percent (7.5%) of the number of shares of Common Stock issuable upon conversion of the Series C Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to fifteen percent (15%) of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock then held by such holder on the fifth full quarter from the closing date.

SEC source: 0001104659-23-057160 · tm2315002-4_4seq1.xml · derivative · entry 2

Matheis Dennis · CIK 0001817012 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50

Underlying: Common Stock · Not disclosed shares

Expires 2026-05-04

F1 · derivative.expiration_date: The Series B Preferred Stock will automatically convert into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.

F2 · derivative.underlying_shares: The Series B Preferred Stock initially converts into shares of common stock at a conversion price of $3.37. In addition, the holders of Series B Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to five percent (5.0%) of the number of shares of Common Stock issuable upon conversion of the Series B Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to ten percent (10%) of the number of shares of common stock issuable upon conversion of the Series B Preferred Stock then held by such holder on the fifth full quarter from the closing date.

SEC source: 0001104659-23-057158 · tm2315002-2_4seq1.xml · derivative · entry 1

KAPLAN JON H. · CIK 0001751699 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30

Underlying: Common Stock · Not disclosed shares

Expires 2026-05-04

F1 · derivative.expiration_date: The Series B Preferred Stock will automatically convert into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.

F2 · derivative.underlying_shares: The Series B Preferred Stock initially converts into shares of common stock at a conversion price of $3.37. In addition, the holders of Series B Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to five percent (5.0%) of the number of shares of Common Stock issuable upon conversion of the Series B Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to ten percent (10%) of the number of shares of common stock issuable upon conversion of the Series B Preferred Stock then held by such holder on the fifth full quarter from the closing date.

SEC source: 0001104659-23-057156 · tm2315002-1_4seq1.xml · derivative · entry 3

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30

Underlying: Common Stock · Not disclosed shares

Expires 2026-05-04

F2 · derivative.expiration_date: The Series B Preferred Stock will automatically convert into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.

F3 · derivative.underlying_shares: The Series B Preferred Stock initially converts into shares of common stock at a conversion price of $3.37. In addition, the holders of Series B Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to five percent (5.0%) of the number of shares of Common Stock issuable upon conversion of the Series B Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to ten percent (10%) of the number of shares of common stock issuable upon conversion of the Series B Preferred Stock then held by such holder on the fifth full quarter from the closing date.

SEC source: 0001104659-23-057159 · tm2315002-3_4seq1.xml · derivative · entry 3

Shaked Yoav · CIK 0001744499 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40

Underlying: Common Stock · Not disclosed shares

Expires 2026-05-04

F2 · derivative.expiration_date: The Series B Preferred Stock will automatically convert into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.

F3 · derivative.underlying_shares: The Series B Preferred Stock initially converts into shares of common stock at a conversion price of $3.37. In addition, the holders of Series B Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to five percent (5.0%) of the number of shares of Common Stock issuable upon conversion of the Series B Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to ten percent (10%) of the number of shares of common stock issuable upon conversion of the Series B Preferred Stock then held by such holder on the fifth full quarter from the closing date.

SEC source: 0001104659-23-004642 · tm233645-1_4seq1.xml · nonDerivative · entry 1

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,112,059

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.23, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

SEC source: 0001104659-22-129915 · tm2233446-1_4seq1.xml · nonDerivative · entry 1

MCGRATH DENNIS M · CIK 0001269340 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,744

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and were effected to pay Federal and State withholding taxes on vested shares.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.12, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

SEC source: 0001104659-22-070253 · tm2218130-1_4seq1.xml · nonDerivative · entry 1

ANDERSON RICHARD ALAN · CIK 0001266647 · President, GM of North America

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,877

F1 · kind: The reported securities were redeemed by the issuer for aggregate proceeds of $170,275, to satisfy certain withholding tax obligations of existing vested restricted stock awards. The redemption of the securities was approved by the Compensation Committee of the issuer and was exempt pursuant to Rule 16b-3.

F1 · price: The reported securities were redeemed by the issuer for aggregate proceeds of $170,275, to satisfy certain withholding tax obligations of existing vested restricted stock awards. The redemption of the securities was approved by the Compensation Committee of the issuer and was exempt pursuant to Rule 16b-3.

SEC source: 0001104659-22-063453 · tm2216123-8_4seq1.xml · derivative · entry 1

STONE RICHARD B · CIK 0001063028 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The options vest over three years in 12 equal quarterly installments following the grant date, subject to the Reporting Person's continued services to the Issuer.

SEC source: 0001104659-22-063445 · tm2216123-2_4seq1.xml · derivative · entry 1

Matheis Dennis · CIK 0001817012 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The options vest over three years in 12 equal quarterly installments following the grant date, subject to the Reporting Person's continued services to the Issuer.

SEC source: 0001104659-22-063449 · tm2216123-4_4seq1.xml · nonDerivative · entry 1

Bacher Dror · CIK 0001710439 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,926

F1 · shares: The shares vest over three years as follows: 8.333% shall vest after 3 months from the grant date, and the remaining shares vest in 11 equal instalments every 3 months thereafter.

SEC source: 0001104659-22-063451 · tm2216123-6_4seq1.xml · nonDerivative · entry 1

Karah Hila · CIK 0001668116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,290

F1 · shares: The shares vest over three years as follows: 8.333% shall vest after 3 months from the grant date, and the remaining shares vest in 11 equal instalments every 3 months thereafter.

SEC source: 0001104659-22-063457 · tm2216123-10_4seq1.xml · nonDerivative · entry 1

Ben-David Zvi · CIK 0001667943 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,035

F1 · shares: The shares vest over three years as follows: 8.333% shall vest after 3 months from the grant date, and the remaining shares vest in 11 equal instalments every 3 months thereafter.

SEC source: 0001104659-22-063450 · tm2216123-5_4seq.xml · nonDerivative · entry 1

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,113,259

F1 · shares: The shares vest over three years as follows: 8.333% shall vest after 3 months from the grant date, and the remaining shares vest in 11 equal instalments every 3 months thereafter.

SEC source: 0001104659-22-063443 · tm2216123-1_4seq1.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,341

F1 · shares: The shares vest over three years as follows: 33.333% shall vest after 12 months from the grant date, and the remaining shares shall vest in 2 equal instalments every 2 years thereafter.

SEC source: 0001104659-22-063447 · tm2216123-3_4seq1.xml · nonDerivative · entry 1

MCGRATH DENNIS M · CIK 0001269340 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,616

F1 · shares: The shares vest over three years as follows: 33.333% shall vest after 12 months from the grant date, and the remaining shares shall vest in 2 equal instalments every 2 years thereafter.

SEC source: 0001104659-22-063452 · tm2216123-7_4seq1.xml · derivative · entry 1

ANDERSON RICHARD ALLAN · CIK 0001266647 · President, GM of North America

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The options vest over three years in 12 equal quarterly installments following the grant date, subject to the Reporting Person's continued services to the Issuer.

SEC source: 0001104659-22-063456 · tm2216123-9_4seq1.xml · nonDerivative · entry 1

Shaked Yoav · CIK 0001744499 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,193

F1 · date: The shares vest over three years as follows: 8.333% shall vest after 3 months from the grant date, and the remaining shares vest in 11 equal instalments every 3 months thereafter.

SEC source: 0001104659-21-136496 · tm2132400d1_4.xml · nonDerivative · entry 2

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 838,259

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.19, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

SEC source: 0001104659-21-137138 · tm2132548-1_4seq1.xml · nonDerivative · entry 1

Bacher Dror · CIK 0001710439 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,926

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 to $19.19, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

SEC source: 0001104659-21-135790 · tm2132279-1_4seq1.xml · nonDerivative · entry 2

Bacher Dror · CIK 0001710439 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,730

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 to $19.09, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

SEC source: 0001104659-21-136496 · tm2132400d1_4.xml · nonDerivative · entry 1

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 839,059

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.01 to $19.09, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

SEC source: 0001104659-21-135188 · tm2132090-1_4seq1.xml · nonDerivative · entry 2

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 839,259

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.02 to $19.10, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

SEC source: 0001104659-21-135790 · tm2132279-1_4seq1.xml · nonDerivative · entry 1

Bacher Dror · CIK 0001710439 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,930

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06 to $19.10, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

SEC source: 0001104659-21-134531 · tm2131978-1_4seq1.xml · nonDerivative · entry 2

Bacher Dror · CIK 0001710439 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,130

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.38, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

SEC source: 0001104659-21-135188 · tm2132090-1_4seq1.xml · nonDerivative · entry 1

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 847,116

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $19.38, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

SEC source: 0001104659-21-133842 · tm2131828-1_4seq1.xml · nonDerivative · entry 2

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 877,599

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.52 to $19.16, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

SEC source: 0001104659-21-134531 · tm2131978-1_4seq1.xml · nonDerivative · entry 1

Bacher Dror · CIK 0001710439 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,146

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.15, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

SEC source: 0001104659-21-133842 · tm2131828-1_4seq1.xml · nonDerivative · entry 1

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 918,878

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.35, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

SEC source: 0001104659-21-126791 · tm2130131d1_4.xml · nonDerivative · entry 1

Cohen Oded · CIK 0001846154 · GM MSK

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,764

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.99 to $16.46, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp.(the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

SEC source: 0001104659-21-125371 · tm2129692d1_4.xml · nonDerivative · entry 1

Bacher Dror · CIK 0001710439 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,509

F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the fourth quarter of 2021.

SEC source: 0001104659-21-125375 · tm2129692d3_4.xml · nonDerivative · entry 1

Ben-David Zvi · CIK 0001667943 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,035

F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the fourth quarter of 2021.

SEC source: 0001104659-21-125373 · tm2129692d2_4.xml · nonDerivative · entry 1

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 944,682

F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the fourth quarter of 2021.

SEC source: 0001104659-21-093981 · tm2122591-1_4seq1.xml · nonDerivative · entry 1

Bacher Dror · CIK 0001710439 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,152

F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the third quarter of 2021.

SEC source: 0001104659-21-093989 · tm2122591-4_4seq1.xml · nonDerivative · entry 1

Ben-David Zvi · CIK 0001667943 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,666

F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the third quarter of 2021.

SEC source: 0001104659-21-093983 · tm2122591-2_4seq1.xml · nonDerivative · entry 1

Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 943,987

F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the third quarter of 2021.